Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive.
Subcutaneous and intracranial VMDk tumours were treated with photodynamic therapy (PDT) using a new sensitiser, m-THPP. Subcutaneous tumours were highly sensitive to PDT but intracranial tumours were much more resistant, requiring a 30-fold increase in sensitiser dose to produce equivalent levels of necrosis. Resistance of intracerebral tumours was not due to failure of the sensitiser to enter tumours. Necrosis of intracranial tumours was increased when mice breathed 100% oxygen during PDT while subcutaneous tumour necrosis was unaffected.
Lindsay
E A
EA
Department of Experimental Pathology, St Mary's Hospital Medical School, London, UK.
Berenbaum
M C
MC
Bonnett
R
R
Thomas
D G
DG
D000818:Animals; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004351:Drug Resistance; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D000860:Hypoxia / Q000209:etiology; D008297:Male; D051379:Mice; D010100:Oxygen / Q000494:pharmacology; D010778:Photochemotherapy; D011166:Porphyrins / Q000032:analysis; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology
D011166:Porphyrins; C051233:5,10,15,20-tetra(3-hydroxyphenyl)porphyrin; D010100:Oxygen